74
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Dengue and Other Common Causes of Acute Febrile Illness in Asia: An Active Surveillance Study in Children

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Common causes of acute febrile illness in tropical countries have similar symptoms, which often mimic those of dengue. Accurate clinical diagnosis can be difficult without laboratory confirmation and disease burden is generally under-reported. Accurate, population-based, laboratory-confirmed incidence data on dengue and other causes of acute fever in dengue-endemic Asian countries are needed.

          Methods and principal findings

          This prospective, multicenter, active fever surveillance, cohort study was conducted in selected centers in Indonesia, Malaysia, Philippines, Thailand and Vietnam to determine the incidence density of acute febrile episodes (≥38°C for ≥2 days) in 1,500 healthy children aged 2–14 years, followed for a mean 237 days. Causes of fever were assessed by testing acute and convalescent sera from febrile participants for dengue, chikungunya, hepatitis A, influenza A, leptospirosis, rickettsia, and Salmonella Typhi. Overall, 289 participants had acute fever, an incidence density of 33.6 per 100 person-years (95% CI: 30.0; 37.8); 57% were IgM-positive for at least one of these diseases. The most common causes of fever by IgM ELISA were chikungunya (in 35.0% of in febrile participants) and S. Typhi (in 29.4%). The overall incidence density of dengue per 100 person-years was 3.4 by nonstructural protein 1 (NS1) antigen positivity (95% CI: 2.4; 4.8) and 7.3 (95% CI: 5.7; 9.2) by serology. Dengue was diagnosed in 11.4% (95% CI: 8.0; 15.7) and 23.9% (95% CI: 19.1; 29.2) of febrile participants by NS1 positivity and serology, respectively. Of the febrile episodes not clinically diagnosed as dengue, 5.3% were dengue-positive by NS1 antigen testing and 16.0% were dengue-positive by serology.

          Conclusions

          During the study period, the most common identified causes of pediatric acute febrile illness among the seven tested for were chikungunya, S. Typhi and dengue. Not all dengue cases were clinically diagnosed; laboratory confirmation is essential to refine disease burden estimates.

          Author Summary

          Acute febrile episodes are common in children living in tropical countries. Diagnosis can be challenging because symptoms of the more common infectious causes are similar and often mimic those of dengue. Asia Pacific has over 70% of the worldwide dengue disease burden, although dengue incidence is generally underestimated because most surveillance systems are passive or based on clinical diagnosis without laboratory confirmation. Understanding the local etiology of febrile illness and the incidence of dengue is important when planning large-scale vaccine trials. This prospective, active fever surveillance, cohort study was carried out in children in five dengue-endemic Asian countries – Indonesia, Malaysia, Philippines, Thailand and Vietnam – during 2010–2011. Acute febrile episodes occurred in 289 (19.3%) of the cohort of 1,500 children. Among the diseases for which antibodies were tested using commercial kits, the top three causes of acute fever were chikungunya, Salmonella Typhi and dengue, followed by influenza A, rickettsia and hepatitis A. Dengue was confirmed in 11.4% of the febrile children by viral protein detection and in 23.9% by serology. Clinical diagnosis was not sufficient to detect all dengue cases. These findings are of relevance to those planning clinical studies of vaccines against these infectious agents in Southeast Asia.

          Related collections

          Most cited references29

          • Record: found
          • Abstract: found
          • Article: not found

          A study of typhoid fever in five Asian countries: disease burden and implications for controls.

          To inform policy-makers about introduction of preventive interventions against typhoid, including vaccination. A population-based prospective surveillance design was used. Study sites where typhoid was considered a problem by local authorities were established in China, India, Indonesia, Pakistan and Viet Nam. Standardized clinical, laboratory, and surveillance methods were used to investigate cases of fever of >or= 3 days' duration for a one-year period. A total of 441,435 persons were under surveillance, 159,856 of whom were aged 5-15 years. A total of 21,874 episodes of fever were detected. Salmonella typhi was isolated from 475 (2%) blood cultures, 57% (273/475) of which were from 5-15 year-olds. The annual typhoid incidence (per 100,000 person years) among this age group varied from 24.2 and 29.3 in sites in Viet Nam and China, respectively, to 180.3 in the site in Indonesia; and to 412.9 and 493.5 in sites in Pakistan and India, respectively. Altogether, 23% (96/413) of isolates were multidrug resistant (chloramphenicol, ampicillin and trimethoprim-sulfamethoxazole). The incidence of typhoid varied substantially between sites, being high in India and Pakistan, intermediate in Indonesia, and low in China and Viet Nam. These findings highlight the considerable, but geographically heterogeneous, burden of typhoid fever in endemic areas of Asia, and underscore the importance of evidence on disease burden in making policy decisions about interventions to control this disease.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine.

            Dengue vaccine development has reached a major milestone with the initiation, in 2010, of the first phase III clinical trial to investigate the Sanofi Pasteur CYD tetravalent dengue vaccine (TDV). The CYD TDV candidate is composed of four recombinant, live, attenuated vaccines (CYD-1-4) based on a yellow fever vaccine 17D (YFV 17D) backbone, each expressing the pre-membrane and envelope genes of one of the four dengue virus serotypes. The vaccine is genetically and phenotypically stable, non-hepatotropic, less neurovirulent than YFV 17D, and does not infect mosquitoes by the oral route. In vitro and in vivo preclinical studies showed that CYD TDV induces controlled stimulation of human dendritic cells, and significant immune responses in monkeys. Scale up and industrialization are being conducted in parallel with preclinical and clinical development to fulfill the needs of phase II/III trials, and to anticipate and facilitate supply and access to vaccine in the countries where the dengue disease burden makes it an urgent public health priority. The vaccine has now been administered to more than 6000 children and adults from dengue endemic and non-endemic areas and no safety concerns have arisen in any of the completed or ongoing trials. A three-dose vaccination regimen induces an immune response against all four serotypes in the large majority of vaccinees. Preexisting flavivirus immunity favors quicker and higher immune responses to CYD TDV, without adversely effecting clinical safety or increasing vaccine viremia. The observed level and nature of the cellular immune responses in humans are consistent with the good safety and immunogenicity profile of the vaccine. Preliminary results of an ongoing, proof-of-concept efficacy and large scale safety study in Thai children are expected by the end of 2012. Here we discuss the different steps and challenges of developing CYD TDV, from research to industrialization, and summarize some of the challenges to the successful introduction of a dengue vaccine into immunization programs. Copyright © 2011 Elsevier Ltd. All rights reserved.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              The pathogenesis of dengue.

              Dengue is an important cause of childhood and adult morbidity in Asian and Latin American countries and its geographic footprint is growing. The clinical manifestations of dengue are the expression of a constellation of host and viral factors, some acquired, others intrinsic to the individual. The virulence of the virus plus the flavivirus infection history, age, gender and genotype of the host all appear to help shape the severity of infection. Similarly, the characteristics of the innate and acquired host immune response subsequent to infection are also likely determinants of outcome. This review summarises recent developments in the understanding of dengue pathogenesis and their relevance to dengue vaccine development. Copyright © 2011 Elsevier Ltd. All rights reserved.
                Bookmark

                Author and article information

                Contributors
                Role: Editor
                Journal
                PLoS Negl Trop Dis
                PLoS Negl Trop Dis
                plos
                plosntds
                PLoS Neglected Tropical Diseases
                Public Library of Science (San Francisco, USA )
                1935-2727
                1935-2735
                July 2013
                25 July 2013
                : 7
                : 7
                : e2331
                Affiliations
                [1 ]Research Institute for Tropical Medicine, Muntinlupa City, Philippines
                [2 ]Chong Hua Hospital, Cebu City, Philippines
                [3 ]Medical Faculty, University of Indonesia, Jakarta, Indonesia
                [4 ]Hospital Kuala Lumpur, Kuala Lumpur, Malaysia
                [5 ]Penang Hospital, Penang, Malaysia
                [6 ]Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand
                [7 ]Department of Child Health, Hasan Sadikin Hospital/School of Medicine Padjadjaran University, Bandung, Indonesia
                [8 ]Armed Forces Research Institute of Medical Sciences (AFRIMS), Bangkok, Thailand
                [9 ]Ho Chi Minh City Pasteur Institute, Ho Chi Minh City, Vietnam
                [10 ]School of Medicine, Udayana University, Bali, Indonesia
                [11 ]Sanofi Pasteur, Clinical Research and Development, Singapore
                [12 ]Sanofi Pasteur, Clinical Research and Development, Makati City, Philippines
                [13 ]Sanofi Pasteur, Clinical Research and Development, Bangkok, Thailand
                Institute of Tropical Medicine, Belgium
                Author notes

                I have read the journal's policy and have the following conflicts. MRC, MNC, SRH, IIHMH, RN, PP, KR, UT, SJT, NHT, DNW, and IKY are investigators in clinical trials of other compounds under development by Sanofi Pasteur. AB, YH, TL and TAW are employees of Sanofi Pasteur, the study sponsor.

                Conceived and designed the experiments: AB YH TL TAW. Performed the experiments: MRC MNC SRH IIHMH RN PP KR UT SJT NHT DNW IKY. Analyzed the data: AB TAW. Wrote the paper: MRC MNC SRH IIHMH RN PP KR UT SJT NHT DNW IKY AB YH TL TAW. Reviewed and approved final manuscript: MRC MNC SRH IIHMH RN PP KR UT SJT NHT DNW IKY AB YH TL TAW.

                Article
                PNTD-D-12-01578
                10.1371/journal.pntd.0002331
                3723539
                23936565
                8dc19d1c-fcdd-475e-984d-1bfe2bc180a3
                Copyright @ 2013

                This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

                History
                : 5 December 2012
                : 14 June 2013
                Page count
                Pages: 9
                Funding
                The study was sponsored by Sanofi Pasteur. The author list includes employees of the study sponsor (AB, YH, TL and TAW); hence, the funders had a role in study design, data collection and analysis, decision to publish, and preparation of the manuscript.
                Categories
                Research Article
                Medicine
                Epidemiology
                Clinical Epidemiology
                Disease Mapping
                Infectious Disease Epidemiology
                Survey Methods
                Infectious Diseases
                Bacterial Diseases
                Salmonella
                Neglected Tropical Diseases
                Dengue Fever
                Tropical Diseases (Non-Neglected)
                Flavivirus
                Viral Diseases
                Influenza

                Infectious disease & Microbiology
                Infectious disease & Microbiology

                Comments

                Comment on this article